Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RCEL vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: RCEL 4 – 1 BMRA (1 Tie) Matrix Metrics: RCEL 8 – 2 BMRA

As of Nov 16, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RCEL carries a Unified Composite Score of 53.1/100 (HOLD) at $15.40 (10.3x Forward P/E, -33.9% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (SURGE options phase, RSI 51.8); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RCEL vs BMRA
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.40
-1.44% 1D
Market Cap $509.0M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.65β · 70% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 71.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (23.0% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $15.94 · SMA50: $13.48
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (RCEL 4 – 1 BMRA)

Columns: Metric · RCEL · BMRA
1. Valuation Multiples RCEL
Forward P/E 10.3x N/M
Trailing P/E 10.3x N/M
PEG Ratio N/M N/M
EV / Revenue 6.4x 1.1x
2. Growth & Scale RCEL
Revenue Growth (YoY) +53.1% -8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $85M $4.3M
Market Cap $509.0M $6.0M
3. Profitability & Quality RCEL
Gross Margin 82.4% 0.9%
Operating Margin -33.9% -125.2%
Net Profit Margin -42.6% -115.5%
Return on Equity (ROE) -1746.3% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$20M -$3.2M
Cash Flow Margin -23.6% -73.5%
Net Cash / Leverage $37M Net Debt $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 78.5% (5th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RCEL (8) vs BMRA (2)
Institutional Metric RCEL BMRA Criterion Row Edge
Market Capitalization
Scale
$509.0M $6.0M Larger Scale RCEL
Trailing P/E Ratio
Valuation
10.3x N/M Lower Multiple RCEL
Forward P/E Ratio
Valuation
10.3x N/M Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+53.1% -8.3% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-33.9% -125.2% Higher Margin RCEL
Net Profit Margin
Profitability
-42.6% -115.5% Higher Margin RCEL
Return on Equity (ROE)
Capital Efficiency
-1746.3% -113.8% Higher ROE BMRA
52-Week Range Position
Momentum
80% ($3–$18) 4% ($1–$3) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
1.65β · 70% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
53.1 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite RCEL
Trailing 12M Revenue (USD)
Operating Scale
$85M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
82.4% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($37M Net Debt) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +46.33 pp
RCEL: +18.14% · BMRA: -28.19%
3M Horizon RCEL +73.37 pp
RCEL: +56.4% · BMRA: -16.97%
6M Horizon RCEL +308.62 pp
RCEL: +267.66% · BMRA: -40.96%
1Y Horizon RCEL +358.76 pp
RCEL: +311.9% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RCEL Revenue BMRA Revenue RCEL Op. Margin BMRA Op. Margin Margin Leader
FY2019 $10M $10M -466.4% -46.4% BMRA
FY2020 $10M $10M -299.2% -41.0% BMRA
FY2021 $30M $10M -90.8% -104.2% RCEL
FY2022 $30M $20M -79.9% -24.0% BMRA
FY2023 $50M $10M -85.1% -135.3% RCEL
FY2024 $60M $10M -88.1% -117.6% RCEL
FY2025 $70M $10M -59.4% -96.7% RCEL
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RCEL SURGE
13d in phase · OBV ACCUMULATION
Current IV 78.5%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $509.0M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RCEL vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RCEL carries a Unified Composite Score of 53.1/100 (HOLD) at $15.40 (10.3x Forward P/E, -33.9% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (SURGE options phase, RSI 51.8); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCEL leads the Growth & Scale pillar: RCEL posts +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), RCEL cumulative revenue shifted +600.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, RCEL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

RCEL screens cheaper on headline valuation multiples. RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCEL (-1746.3% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, RCEL carries 78.5% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.65β · 70% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.